New Wave Wealth Advisors LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

New Wave Wealth Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 366 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. West Paces Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the last quarter. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $28,000. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $33,000. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold a total of 8,033 shares of company stock worth $9,399,345 over the last ninety days. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of REGN opened at $1,051.24 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock has a market capitalization of $115.83 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 3.57 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The business’s 50 day simple moving average is $1,128.54 and its 200-day simple moving average is $1,036.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same period last year, the company posted $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research analyst reports. Barclays lifted their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Leerink Partners restated a “market perform” rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. TD Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,118.62.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.